Dravet SyndromeSymptoms, Doctors, Treatments, Advances & More
Learn About Dravet Syndrome
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Atrium Health Neurology Specialty Care
Rajdeep Singh is a Neurologist practicing medicine in Charlotte, North Carolina. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Dravet Syndrome. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Seizures, Memory Loss, Dravet Syndrome, and Epilepsy. Dr. Singh is board certified in American Board Of Psychiatry And Neurology. Dr. Singh is currently accepting new patients.
Children's Hospital Colorado
Kelly Knupp is a Pediatrics provider practicing medicine in Aurora, Colorado. She has been practicing medicine for over 29 years. Dr. Knupp is rated as an Elite provider by MediFind in the treatment of Dravet Syndrome. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses West Syndrome, Myoclonic Epilepsy, Spasmus Nutans, and Dravet Syndrome. Dr. Knupp is board certified in American Board Of Psychiatry And Neurology and American Board Of Psychiatry And Neurology. Dr. Knupp is currently accepting new patients.
Werner K Doyle M.D. PC
Orrin Devinsky is a Neurologist practicing medicine in New York, New York. Dr. Devinsky is rated as an Elite provider by MediFind in the treatment of Dravet Syndrome. He is also highly rated in 31 other conditions, according to our data. His clinical expertise encompasses Myoclonic Epilepsy, Dravet Syndrome, Seizures, Epilepsy, and Deep Brain Stimulation.
Summary: ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1A), aged ≥48 months to \<18 years (Part 1B), and aged ≥6 to \<48 months (Part 2). Part 1A follows an open-label, dose-escalation design, Part 1B follows an open-label design, and Part 2 is a randomized, double-blind, sham...
Summary: This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. ...